



UNITED STATES PATENT AND TRADEMARK OFFICE

JM J  
AKBM-32917/US-11  
REX

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

DO NOT USE IN PALM PRINTER

MAILED

(THIRD PARTY REQUESTER'S CORRESPONDENCE ADDRESS)

DEC 21 2012

CASIMIR JONES, S.C.

CENTRAL REEXAMINATION UNIT

2275 DEMING WAY,

SUITE 310

MIDDLETON, WI 53562

**EX PARTE REEXAMINATION COMMUNICATION TRANSMITTAL FOR IV.**

REEXAMINATION CONTROL NO. 90/012,698.

PATENT NO. 8278351.

ART UNIT 3991.

DEC 26 2012

Enclosed is a copy of the latest communication from the United States Patent and Trademark Office in the above identified *ex parte* reexamination proceeding (37 CFR 1.550(f)).

Where this copy is supplied after the reply by requester, 37 CFR 1.535, or the time for filing a reply has passed, no submission on behalf of the *ex parte* reexamination requester will be acknowledged or considered (37 CFR 1.550(g)).

Petition for Inter Partes Review  
Of U.S. Patent 8,278,351  
Exhibit  
**ENZYMOTEC - 1065**

<b>Order Granting / Denying Request For Ex Parte Reexamination</b>	<b>Control No.</b> 90/012,698	<b>Patent Under Reexamination</b> 8278351
	<b>Examiner</b> BRUCE CAMPELL	<b>Art Unit</b> 3991

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

The request for *ex parte* reexamination filed 02 October 2012 has been considered and a determination has been made. An identification of the claims, the references relied upon, and the rationale supporting the determination are attached.

Attachments: a)  PTO-892,      b)  PTO/SB/08,      c)  Other: \_\_\_\_\_

1.  The request for *ex parte* reexamination is GRANTED.

RESPONSE TIMES ARE SET AS FOLLOWS:

For Patent Owner's Statement (Optional): TWO MONTHS from the mailing date of this communication (37 CFR 1.530 (b)). **EXTENSIONS OF TIME ARE GOVERNED BY 37 CFR 1.550(c).**

For Requester's Reply (optional): TWO MONTHS from the **date of service** of any timely filed Patent Owner's Statement (37 CFR 1.535). **NO EXTENSION OF THIS TIME PERIOD IS PERMITTED.** If Patent Owner does not file a timely statement under 37 CFR 1.530(b), then no reply by requester is permitted.

2.  The request for *ex parte* reexamination is DENIED

This decision is not appealable (35 U.S.C. 303(c)). Requester may seek review by petition to the Commissioner under 37 CFR 1.181 within ONE MONTH from the mailing date of this communication (37 CFR 1.515(c)). **EXTENSION OF TIME TO FILE SUCH A PETITION UNDER 37 CFR 1.181 ARE AVAILABLE ONLY BY PETITION TO SUSPEND OR WAIVE THE REGULATIONS UNDER 37 CFR 1.183.**

In due course, a refund under 37 CFR 1.26 ( c ) will be made to requester:

- a)  by Treasury check or,
- b)  by credit to Deposit Account No. \_\_\_\_\_, or
- c)  by credit to a credit card account, unless otherwise notified (35 U.S.C. 303(c)).

/Bruce Campell/ Primary Examiner, Art Unit 3991		
--	--	--

cc:Requester ( if third party requester )

### Request for Ex Parte Reexamination

A request for *ex parte* reexamination of claims 1-94 of U.S. Patent 8,278,351 was filed October 2, 2012 by a third party requester.


### Decision on Request

A substantial new question of patentability (SNQ) affecting claims 1-94 of United States Patent Number 8,278,351 is raised by the request for *ex parte* reexamination.


### Claims

In reexamination, patent claims are construed broadly. In *re Yamamoto*, 740 F.2d 1569, 1571, 222 USPQ 934, 936 (Fed. Cir. 1984) (claims given "their broadest reasonable interpretation consistent with the specification"). This Request is directed to claims 1-94 of U.S. Patent 8,278,351. Claim 1 is representative:

1. A krill extract comprising:  
a phospholipid of the general formula (I)



wherein R1 and R2, each together with the respective carboxyl groups to which each is attached, each independently represents a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue, and X is  $-\text{CH}_2\text{CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$ , or



and  
wherein the extract is suitable for human consumption.

***Documents Submitted by Requester***

The following documents were submitted by Requester as the basis for this Request.

WO 00/23546, published April 27, 2000 by Beaudoin et al. (Beaudoin I)

Canadian Application 2,251,265, published April 21, 2000 by Beaudoin et al. (Beaudoin II)

WO 97/39759, published October 30, 1997 by Stoll

Neptune Final Prospectus dated May 11, 2001

Neptune Press Release dated June 14, 2001

Beaudoin I was applied in a rejection during prosecution of the '351 patent. Beaudoin II and Stoll were cited in an information disclosure statement but not relied upon by the examiner. None of the other references were considered during prosecution of the '351 patent.

Requester has also submitted evidentiary declarations under 37 CFR 1.132 by Bjørn Ole Haugsgjerd, Richard B. van Breemen and Ivar Storrø.

***Requester's Proposed SMOs***

1. Requester considers claims 1-94 unpatentable over the **Neptune final prospectus** as evidenced by Beaudoin I and the Haugsgjerd, van Breemen and Storrø declarations (Request, pp. 8-40).

The **Neptune final prospectus** is a prospectus for a stock offering by Neptune, the assignee of the '351 patent and apparently the licensee of the Beaudoin applications / patents. The prospectus describes in general terms Neptune's krill oil product and the method by which it is made, and cites the Beaudoin applications (pp. 11-14). The prospectus does not disclose that the Neptune krill oil contains lipids as recited in the '351 patent claims. Beaudoin I, which Requester cites as "evidence," was

applied in a rejection during prosecution of the '351 patent (discussed further below). Therefore the prospectus does not appear to disclose any new technical information that was not considered during examination of the '351 patent. The Haugsgjerd and van Breemen declarations do not discuss the Neptune prospectus and are therefore not evidence relating to the prospectus. Similarly, the Storrø declaration cites the prospectus in its explanation of what Beaudoin I discloses, but does not provide any evidence regarding the prospectus.

Because it does not disclose any new technical information not previously considered by the Office during prosecution of the '351 patent, the Neptune final prospectus does not raise a SNQ with regard to claims 1-94.

2. Requester considers claims 1-94 unpatentable over the **Neptune press release** as evidenced by Beaudoin I and the Haugsgjerd, van Breemen and Storrø declarations (Request, pp. 40-71).

The **Neptune press release** announces that Neptune "has reached the final stage to obtain a patent" based, apparently, on the Beaudoin applications. The press release describes in general terms Neptune's krill oil product and the method by which it is made. The press release does not disclose that the Neptune krill oil contains lipids as recited in the '351 patent claims. Beaudoin I, which Requester cites as "evidence," was applied in a rejection during prosecution of the '351 patent (discussed further below). Therefore the press release does not appear to disclose any new technical information that was not considered during examination of the '351 patent. The Haugsgjerd, van Breemen and Storrø declarations do not discuss the Neptune press release and are therefore not evidence relating to the press release.

Because it does not disclose any new technical information not previously considered by the Office during prosecution of the '351 patent, the Neptune press release does not raise a SNQ with regard to claims 1-94.

3. Requester considers claims 1-94 unpatentable over **Beaudoin I** alone, as evidenced by the Neptune final prospectus and the Haugsgjerd, van Breemen and

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.